Amyloid-beta(1-42) fibrillar precursors are optimal for inducing tumor necrosis factor-alpha production in the THP-1 human monocytic cell line.
Pathological studies have determined that fibrillar forms of amyloid-beta protein (Abeta) comprise the characteristic neuritic plaques in Alzheimer's disease (AD). These studies have also revealed significant inflammatory markers such as activated microglia and cytokines surrounding the plaques. Although the plaques are a hallmark of AD, they are only part of an array of Abeta aggregate morphologies observed in vivo. Interestingly, not all of these Abeta deposits provoke an inflammatory response. Since structural polymorphism is a prominent feature of Abeta aggregation both in vitro and in vivo, we sought to clarify which Abeta morphology or aggregation species induces the strongest proinflammatory response using human THP-1 monocytes as a model system. An aliquot of freshly reconstituted Abeta(1-42) in sterile water (100 microM, pH 3.6) did not effectively stimulate the cells at a final Abeta concentration of 15 microM. However, quiescent incubation of the peptide at 4 degrees C for 48-96 h greatly enhanced its ability to induce tumor necrosis factor-alpha (TNFalpha) production, the level of which surprisingly declined upon further aggregation. Imaging of the Abeta(1-42) aggregation solutions with atomic force microscopy indicated that the best cellular response coincided with the appearance of fibrillar structures, yet conditions that accelerated or increased the level of Abeta(1-42) fibril formation such as peptide concentration, temperature, or reconstitution in NaOH/PBS at pH 7.4 diminished its ability to stimulate the cells. Finally, depletion of the Abeta(1-42) solution with an antibody that recognizes fibrillar oligomers dramatically weakened the ability to induce TNFalpha production, and size-exclusion separation of the Abeta(1-42) solution provided further characterization of an aggregated species with proinflammatory activity. The findings suggested that an intermediate stage Abeta(1-42) fibrillar precursor is optimal for inducing a proinflammatory response in THP-1 monocytes.
Ajit
Deepa
D
Department of Chemistry and Biochemistry and Center for Nanoscience, University of Missouri, St. Louis, Missouri 63121, USA.
Udan
Maria L D
ML
Paranjape
Geeta
G
Nichols
Michael R
MR
D000544:Alzheimer Disease / Q000209:etiology / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D002460:Cell Line; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D018625:Microscopy, Atomic Force; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D010446:Peptide Fragments / Q000737:chemistry / Q000378:metabolism* / Q000494:pharmacology; D011498:Protein Precursors / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D020836:Protein Structure, Quaternary; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D016229:Amyloid beta-Peptides; D018836:Inflammation Mediators; D010446:Peptide Fragments; D011498:Protein Precursors; D014409:Tumor Necrosis Factor-alpha; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42)
J Biol Chem. 2005 Jan 28;280(4):2471-80
15528204
FASEB J. 2004 Jan;18(1):203-5
14597556
J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5
12933918
Mol Neurodegener. 2007 Sep 26;2:18
17897471
Neurobiol Aging. 2009 Nov;30(11):1792-804
18339452
Nat Med. 2001 Mar;7(3):369-72
11231639
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):4012-7
19228947
Nat Rev Neurosci. 2007 Jul;8(7):499-509
17551515
J Biol Chem. 2002 Aug 30;277(35):32046-53
12058030
Biochemistry. 2003 Mar 25;42(11):3151-9
12641446
Anal Biochem. 1976 May 7;72:248-54
942051
Neurosci Lett. 1987 Aug 18;79(1-2):195-200
3670729
Nature. 2008 Feb 7;451(7179):720-4
18256671
J Neurosci. 2001 Feb 15;21(4):1179-88
11160388
Nature. 1996 Aug 22;382(6593):716-9
8751442
J Biol Chem. 2003 Mar 28;278(13):11612-22
12499373
J Biol Chem. 1999 Sep 3;274(36):25945-52
10464339
J Neurochem. 2000 Mar;74(3):1017-25
10693932
Nature. 2002 Apr 4;416(6880):535-9
11932745
Nat Rev Mol Cell Biol. 2007 Feb;8(2):101-12
17245412
Biochemistry. 1999 Jul 13;38(28):8972-80
10413470
Chem Biol. 1997 Feb;4(2):119-25
9190286
Nature. 1995 Apr 13;374(6523):647-50
7715705
J Neuroimmunol. 1996 Jun;67(1):21-9
8707927
Brain Res. 1997 Jan 30;747(1):114-21
9042534
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12243-7
7991613
Am J Pathol. 1964 Feb;44:269-97
14119171
J Neurosci. 2006 May 31;26(22):6011-8
16738244
Cancer Res. 1988 Sep 1;48(17):4827-33
3409223
J Mol Biol. 2004 Jan 2;335(1):247-60
14659754
Nature. 1996 Aug 22;382(6593):685-91
8751438
Science. 2003 Apr 18;300(5618):486-9
12702875
J Biol Chem. 2006 Feb 17;281(7):4292-9
16361260
Neurobiol Aging. 2001 Nov-Dec;22(6):837-42
11754990
J Neurosci. 2003 Apr 1;23(7):2665-74
12684452
Cell Physiol Biochem. 2007;20(6):947-56
17982277
Biochemistry. 2002 May 14;41(19):6115-27
11994007
J Biol Chem. 1997 Aug 29;272(35):22364-72
9268388
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1485-90
11818542
Cell. 1993 Jun 18;73(6):1055-8
8513491
Biochemistry. 2000 Nov 14;39(45):13748-59
11076514
Trends Cell Biol. 1998 Nov;8(11):447-53
9854312
Nat Cell Biol. 2004 Nov;6(11):1054-61
15516999
Nat Struct Biol. 1995 Nov;2(11):990-8
7583673
Nat Med. 2002 Sep;8(9):936-8
12205453
Methods Mol Biol. 2005;299:19-33
15980593
J Neurochem. 2008 Jan;104(2):524-33
17986235
Science. 2005 Jan 14;307(5707):262-5
15653506
Brain Res. 1991 Nov 1;563(1-2):311-4
1786545
Exp Gerontol. 1998 Aug;33(5):371-8
9762518
Glia. 1993 Jan;7(1):75-83
8423065